1. Gilliland DG, Griffin JD (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood 100:1532–1542
2. Fabbro D, Ruetz S, Bodis S, Pruschy M, Csermak K, Man A, Campochiaro P, Wood J, O’Reilly T, Meyer T (2000) PKC412–a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 15:17–28
3. Manley PW, Boulton C, Caravatti G, Gilliland DG, Griffin J, Kung A, Kelly L, Maira M, Mestan J, Meyer T, Ruetz S, Weisberg E, Fabbro D (2003) Preclinical profile of PKC412 (Midostaurin) as an FLT3 inhibitor for the therapy of AML. In: 94th AACR annual meeting, poster 1004
4. Levis M, Brown P, Smith BD, Stine A, Pham R, Stone R, Deangelo D, Galinsky I, Giles F, Estey E, Kantarjian H, Cohen P, Wang Y, Roesel J, Karp JE, Small D (2006) Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 108:3477–3483
5. Yin OQ, Wang Y, Schran H (2008) A mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjects. Clin Pharmacokinet 47:807–816